J&J’s Incivo Shows “Hints” Of Added Benefit, Says Germany’s IQWiG
This article was originally published in The Pink Sheet Daily
IQWiG concludes that J&J/Vertex’s new Hep C drug Incivo might be helpful in certain patient groups, but the German HTA body questions the validity of a widely-used surrogate efficacy measure.
You may also be interested in...
Intermune’s Esbriet Flops In Front Of IQWiG
Germany’s IQWiG remains unconvinced about the added value offered by Intermune’s Esbriet, a decision that adds to industry concerns on assessment methodology
AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.